Abstract: Major depressive disorder (MDD) is a disabling psychiatric condition for which effective treatment remains an outstanding need. Antidepressants are currently the mainstay of treatment for depression; however, almost two-thirds of patients will fail to achieve remission with initial treatment. As a result, a range of augmentation and combination strategies have been used in order to improve outcomes for patients. Despite the popularity of these approaches, limited data from double-blind, randomized, placebo-controlled studies are available to allow clinicians to determine which are the most effective augmentation options or which patients are most likely to respond to which options. Recently, evidence has shown that adjunctive therapy with atypical antipsychotics has the potential for benefi cial antidepressant effects in the absence of psychotic symptoms. In particular, aripiprazole has shown effi cacy as an augmentation option with standard antidepressant therapy in two, large, randomized, double-blind studies. Based on these effi cacy and safety data, aripiprazole was recently approved by the FDA as adjunctive therapy for MDD. The availability of this new treatment option should allow more patients with MDD to achieve remission and, ultimately, long-term, successful outcomes.
Introduction
Effective treatment of patients with major depressive disorder (MDD) remains an outstanding need in psychiatry. In the past, adjunctive antipsychotics were used primarily for treating psychotic symptoms in patients with MDD. However, current evidence indicates that these agents have antidepressant effects in patients with non-psychotic major depression. Recently, the atypical antipsychotic aripiprazole received approval from the Food and Drug Administration (FDA) as adjunctive therapy for patients with MDD. Given these developments, this review of the need for augmentation strategies, the range of options available, and the clinical evidence base for aripiprazole as the newest adjunctive medication for MDD was undertaken.
Epidemiology and disease burden
Major depressive disorder is a common and disabling psychiatric condition (Murray and Lopez 1996) . Current estimates for lifetime prevalence of MDD range from 17% to 18%, making it one of the most prevalent mental health disorders . According to the Global Burden of Disease Study Lopez 1996, 1997) , depression currently ranks as the fourth leading cause of global disease burden, with the disorder affecting 13-14 million adults in the United States in a given year . By 2020, depression is projected to be the second leading cause of disease burden worldwide after heart disease. Furthermore, MDD is associated with high morbidity and mortality; for example, up to 15% of individuals with more severe forms of this disorder die by suicide (APA 2000) . MDD also incurs huge health care costs: in 2000, depression (major depressive disorder, bipolar depression or dysthymia) incurred an estimated cost of US $83.1 billion, which was related to treatment costs, loss of productivity and suicide-related costs (Greenberg et al 2003) . Another study that excluded bipolar depression found that employees with MDD have costs of lost work time totaling US$31 billion compared with peers without depression (Stewart et al 2003) .
Depression comorbid with other chronic diseases, such as diabetes and arthritis, worsens overall health and wellbeing. Several studies have shown that there is an increased risk of major depression in individuals with one or more chronic diseases (Katon and Schulberg 1992; Noel et al 2004; Harpole et al 2005; Katon et al 2007) . Indeed, data suggest that there is an interactive/synergistic effect between depression and chronic medical conditions, resulting in a negative effect on health beyond a simple additive effect of each condition (Moussavi et al 2007) . In addition, depression aggravates the course of various medical conditions, even increasing mortality in patients with heart disease and stroke (Frasure-Smith et al 1993; Morris et al 1993) .
If left untreated, depression may develop a chronic course or be recurrent, and over time be associated with increasing disability (Andrews 2001 , Solomon et al 2000 . Given the prevalence, chronicity and associated disability of MDD, there has been an increased focus on the development of new and more effective treatment options for this condition.
Diagnosis and neurobiology
MDD is a complex disease state with variable symptoms, presentation, features, and course. This variability is a challenge to the clinician and complicates diagnosis. The DSM-IV-TR defi nes MDD as the presence of single or multiple major depressive episodes once schizophrenia, schizoaffective disorder, delusional disorders, bipolar illness and episodes due to substance abuse or medical illness have been excluded (APA 2000) .
Major depression is a heterogeneous disorder and, to date, causal mechanisms remain unclear. Psychological, biological, and environmental factors have all been shown to contribute to the development of MDD. For example, a recent review of twin studies estimated that about 37% of the risk of MDD is inherited (Sullivan et al 2000) .
The early observation that many compounds that inhibit monoamine reuptake have antidepressant properties suggested that these neurotransmitters may be involved in the etiology of depression. Subsequently, many abnormalities in the serotonin, norepinephrine, and dopamine systems have been identifi ed but it remains unclear which are primary, which are compensatory, and which are changes unrelated to depression (Belmaker and Agam 2008) . A possible role for serotonin, norepinephrine, and dopamine in various behaviors associated with depression has been suggested by animal studies; yet, to date, these relationships have not been validated in depressed human patients. In fact, a comparison of the symptom effects of two antidepressants selective for different neurotransmitters -serotonin and norepinephrine -found no differences in the symptoms that improved, suggesting that they both may act through a fi nal common pathway (Nelson et al 2005) .
Alternatively, the role of neurotransmitters in the mediation of antidepressant action is relatively better established. Studies that use tryptophan depletion to lower serotonin and alpha-methyl-paratyrosine to inferfere with the synthesis of catecholamines indicate that serotonin, norepinephrine, and dopamine are involved in the mechanism of action of most antidepressant compounds (Delgado et al 1990; Miller et al 1996) .
Treatment and management

Treatment goals
Once a patient is diagnosed with MDD, treatment of MDD should aim to achieve full resolution of symptoms and full restoration of psychosocial and occupational functioning. Treatment initially focuses on the rapid resolution of symptoms during the acute phase with the goal of remission. As the patient moves into continuation therapy, the goal is to maintain remission and prevent relapse. Remission represents a pivotal stepping stone on the road to recovery and is the key goal of pharmacological treatment (Figure 1 ).
Early achievement of symptomatic remission is critical to the long-term success of treatment (Kupfer 2005) . Residual symptoms and partial response are associated with an increased risk of relapse, faster time to relapse, a more severe and chronic course, and increased functional impairment (social, occupational, home life) (Paykel et al 1995; Papakostas et al 2004) . The importance of achieving remission has been well illustrated in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. As shown in Figure 2 , at each treatment level, patients who achieved remission were less likely to relapse than those not achieving remission (Rush et al 2006; Rush 2007) . Collectively, these data validate the importance of remission as a clinically meaningful endpoint.
Augmentation treatment in MDD Treatments
Antidepressants are currently the mainstay of treatment for depression and depressive episodes. Many different classes of antidepressants exist, including monoamine oxidase inhibitors (MOAIs), tricyclic antidepressants (TCAs), serotonin modulators, selective serotonin reuptake inhibitors (SSRIs), dopamine-norepinephrine reuptake inhibitors (DNRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and norepinephrine-serotonin modulators. The effectiveness of antidepressant medications is generally comparable. Although a possible advantage for dual-action agents has been suggested, a meta-analysis of 93 studies comparing dual-action agents with SSRIs found the advantage, although signifi cant, was small, with a pooled response rate of 63.6% for dual-action agents vs 59.3% for SSRIs (Papakostas et al 2007b) .
Despite the availability of more than two dozen different antidepressants, these treatments often yield inadequate results. Up to 70% of patients with MDD do not reach remission with an adequate course of one antidepressant and experience poorer long-term outcomes (Fava 2003 In remission (QIDS-SR score ≤5) Not in remission Relapse rate (%)
Step 1 (n = 3,671) (n = 1,439) (n = 390) (n = 123)
Step 2
Step 3 Step 4 that, with each failed treatment trial, remission rates declined. Remission rates after two or three failed treatments averaged less than 15% (Rush et al 2006) . According to American Psychiatric Association (APA) practice guidelines, if a patient with MDD has not responded to treatment or achieved only a partial response to treatment after 4-8 weeks of therapy during the acute phase, a change in dose, a switch to a new drug, or augmentation therapy is recommended (American Psychiatric Association 2000) . A range of augmentation and combination strategies have been used Rush et al 2004) . The challenge for clinicians is to tailor and adjust treatment options for individual patients in order to identify the most appropriate treatment approach.
Augmentation and combination strategies
Both augmentation and combination strategies have been used in patients with major depression. Combination strategies are those that use two antidepressants, each of which is approved as monotherapy. Augmentation strategies add an agent that is not conventionally used as fi rst-line monotherapy (ie, atypical antipsychotic, lithium, T3) to an antidepressant. Augmentation and combination strategies have been proposed on the assumption that such combinations may have additive or synergistic effects (Rush et al 2006; Rutherford et al 2007) . Furthermore, addition of a second agent in a partial responder has the practical advantage of maintaining any improvement made and may result in a rapid response. Notably, the effi cacy of augmentation and combination treatments is not limited to partial responders, but has been less well studied in non-responders. For the purpose of this review article, we recognize the terms "augmentation" and "adjunctive" as similar in meaning and may use them interchangeably throughout the text.
Although combination approaches are commonly used, the evidence base is quite limited. The popular combination of bupropion and SSRI has not been examined in placebo-controlled studies. "Best evidence" is limited to an open-label, randomized comparison study in STAR*D . Similarly, the best evidence for the combination of venlafaxine and mirtazapine is an openlabel, randomized comparison (McGrath et al 2006) . The combination of mirtazapine and an SSRI has been studied and found effective in two controlled studies of 26 and 62 patients, respectively (Carpenter et al 2002; Blier et al 2003) . Desipramine added to fl uoxetine has been demonstrated to be effective in a small study of 39 inpatients (Nelson et al 2004) , but only half of the sample were previously treatment resistant. Overall, controlled trials of combination strategies are limited in number, are limited in sample size (largest is n = 62), and are variable in their requirements for prior treatment resistance.
A variety of agents have been used to augment antidepressants. The most frequently studied strategies are lithium, thyroid, stimulants, buspirone, pindolol, and omega-3 fatty acids. Addition of stimulants is one of the oldest strategies and most studies were small, open-label, and added dextroamphetamine or methylphenidate to a tricyclic or an MAOI. A recent placebo-controlled, double-blind trial in 60 patients augmented an SSRI with methylphenidate but failed to fi nd a signifi cant advantage for the augmentation approach (Patkar et al 2006a) . Open-label studies of buspirone and pindolol suggested effi cacy but a controlled trial of buspirone failed (Landen et al 1998) , as did two controlled trials of pindolol in treatment-resistant patients (Moreno et al 1997; Perez et al 1999) .
Lithium augmentation was the fi rst approach suggested on the basis of a neurochemical rationale (De Montigny et al 1981) . Subsequently, lithium augmentation has been studied in 10 placebo-controlled trials and a meta-analysis of these trials has been reported (Crossley and Bauer 2007) . Although the meta-analysis showed evidence of effi cacy, the value of lithium augmentation continues to be debated. The largest controlled lithium study included 61 patients but all the others were small studies (Յ35 patients). Few included clearly resistant patients, and the only study that did include treatment-resistant patients failed to fi nd any advantage for lithium (Nierenberg et al 2003) . Addition of triiodothyronine (T3) has also received considerable attention. A recent metaanalysis of T3 studies found evidence for effi cacy; however, when limited to placebo-controlled trials, only 75 patients were studied in four trials and the difference between T3 and placebo was not signifi cant (Aronson et al 1996) . All of these controlled trials added T3 to a tricyclic antidepressant. In the open, randomized STAR*D comparison (Nierenberg et al 2006) , thyroid was signifi cantly better tolerated than lithium augmentation and appeared to be effective. The other augmentation strategy with a growing literature is the addition of omega-3 fatty acids. Although results were variable, a meta-analysis and review document only ten double-blind, placebo-controlled studies in 329 patients with mood disorders who were receiving omega-3 PUFAs for Ն4 weeks (Lin and Su 2007) . The results demonstrated a signifi cant effect for omega-3-fatty acid but signifi cant heterogeneity was noted, as was an indication of publication bias. Study designs, patient samples, dosing, and omega-3 constituents Augmentation treatment in MDD were variable. Finally, as with several other strategies, the effi cacy of omega-3 in antidepressant-resistant patients needs further study.
Although other augmentation strategies have been suggested, the data for these are more limited. One large trial (n = 308) of modafi nil in SSRI partial responders with prominent fatigue and sleepiness did show the drug to be more effective than placebo (Fava et al 2005) . One controlled trial of folate in 127 depressed patients showed signifi cant effi cacy in women but not in men (Coppen and Bailey 2000) . Augmentation studies of testosterone have been negative. Augmentation with estrogen or estrogen/progesterone combinations in post-or peri-menopausal women have been inconsistent (Morgan et al 2005 , Dias et al 2006 .
Atypical augmentation
Prior to 1980, more than 30 studies explored the use of typical antipsychotics in MDD (Nelson 1987) . These trials are limited particularly by the use of earlier diagnostic systems; nevertheless, the fi ndings suggested that patients experienced some relief with these agents. They were never recognized as true antidepressants, perhaps because they were not effective for treatment of two core symptoms of depression -loss of interest and motor retardation (Raskin et al 1970) . Two formulations of an antipsychotic (perphenazine) and an antidepressant (amitriptyline) were licensed for use in depression. However, the use of the typical antipsychotics in non-psychotic depression declined rapidly during the 1980s with recognition of their risk of tardive dyskinesia.
The advent of second-generation antipsychotics with an improved safety profi le has prompted their exploration as effective agents for the treatment of MDD. In 1999, Ostroff and Nelson reported the apparent value of adding risperidone in 8 outpatients who had not responded to an SSRI (Ostroff and Nelson 1999) . In 2001, Shelton et al reported the fi rst controlled study of olanzapine and fl uoxetine vs either drug with placebo in 28 patients showing an advantage for the combination (Shelton et al 2001) . Subsequently, a number of open and controlled studies followed. In 2007, Papakostas et al published a review and meta-analysis of atypical augmentation studies (Papakostas et al 2007a) . They found 10 studies (olanzapine 5, quetiapine 3, risperidone 2). The studies included 4 smaller samples of 15-58 patients and 6 larger samples of 100-303 patients. All included patients with non-psychotic major depression. Different from the previous literature, several of these studies required evidence of prior treatment failure, usually to one historical and one prospective treatment trial. The meta-analysis found that the trials as a group demonstrated effi cacy, although several individual studies did not (Figure 3) . The risk ratio for remission comparing atypical antipsychotics with placebo was 1.75 (95% CI 1.36, 2.24; p Ͻ 0.0001) and for response was 1.35 (95% CI 1.13, 1.63; p = 0.001). Pooled remission rates were 47.2% and 22.3% for the atypical agents and placebo, respectively. Pooled response rates were 57.2% and 35.4%, respectively. Although this meta-analysis showed no difference in overall discontinuation rates between atypical antipsychotics and placebo, the rate of discontinuations due to adverse events was more than three-fold higher in patients treated with atypical antipsychotic agents than placebo (p Ͻ 0.0001).
Aripiprazole represents one of the most recently developed second-generation atypical antipsychotics. Effi cacy for aripiprazole augmentation in depression was demonstrated in two large, randomized, double-blind 14-week studies (Berman et al 2007b; Marcus et al 2008) . A third study is currently ongoing. Table 1 . This program provides the most rigorous dataset available for any single agent evaluated for augmentation treatment of MDD, supported by large patient populations, randomized and placebo-controlled study designs, and implementation of historical and prospective demonstration of antidepressant unresponsiveness (Table 1 ). The remainder of this review focuses on the fi ndings of these studies.
Focus on aripiprazole Pharmacological rationale
Although the mechanism of action of augmentation is not well understood, it is possible that the distinct pharmacological profi le of aripiprazole may make it a suitable adjunctive agent for the treatment of MDD. Differing from conventional antipsychotics, which were thought to have essentially a one-dimensional effect related to D 2 antagonism, the atypical drugs have neuropharmacologic profi les that are quite different and may have different implications in depression. Thus, although these agents appear to have similar effi cacy in schizophrenia, it is not clear that they have similar effi cacy in depression. For example, all of the atypical agents have 5-HT 2 antagonist effects that might contribute to antidepressant effects. The synergistic effects of olanzapine and fl uoxetine on synaptic levels of 5HT, NE, and dopamine may be useful, and for ziprasidone the possible addition of 5-HT and norepinephrine reuptake blockade is of potential interest. For aripiprazole, the interesting features are its partial-agonist activity at the D 2 /D 3 receptors, in addition to partial-agonist activity at the serotonin 1A (5-HT 1A ) receptor (Shapiro et al 2003; Jordan et al 2004 , Stark et al 2007 . An agent, such as aripiprazole, that engages several mechanisms of action might be particularly effective in depression; however, all of these possible synergies are hypothetical and it is unclear how they translate into clinical effi cacy.
Pharmacokinetics and dosing
Pharmacokinetic interaction studies have shown that aripiprazole 2-20 mg/kg does not affect the clearance of escitalopram, fl uoxetine, paroxetine, sertraline, or venlafaxine; thus, no dosage adjustment is required for these antidepressants when aripiprazole is added. Across four studies, aripiprazole had no clinically meaningful effects on the pharmacokinetics of these standard antidepressant therapies (escitalopram, 10-20 mg/day; fl uoxetine, 20-40 mg/day; paroxetine controlled-release, 37.5-50 mg/day; sertraline, 100-150 mg/day; or venlafaxine extended-release, 150-225 mg/day) in either healthy subjects or patients with MDD (personal communication/manuscript submitted). However, fl uoxetine and paroxetine are both inhibitors of CYP2D6, and are likely to increase aripiprazole plasma levels (Abilify 2007) . The pivotal augmentation studies used the same fl exible-dose design. Patients randomized to receive adjunctive aripiprazole were treated with a starting dose of 5 mg/day, which could be increased weekly in 5 mg/day increments to a maximum dose of 15 mg/day (patients receiving fl uoxetine or paroxetine CR, due to their CYP2D6 inhibition increasing aripiprazole levels) or 20 mg/day (all other patients) based on assessment of tolerability and clinical response. If tolerated, all patients were to receive a target minimum dose of 10 mg/day. Doses could be decreased at any visit, based on tolerability; patients unable to tolerate 5 mg/day could have their dose decreased to 2 mg/day. The FDA have approved an initial dose of adjunctive aripiprazole 
Effi cacy
In patients with major depression without psychosis who showed an inadequate response to ADT, adjunctive aripiprazole has been shown to augment antidepressant effi cacy in two 14-week, double-blind, randomized trials of identical design (Berman et al 2007b; Marcus et al 2008) . The studies comprised a screening phase, an 8-week prospective treatment phase, and a 6-week randomization phase. During prospective treatment, patients received escitalopram, fl uoxetine, paroxetine controlled-release, sertraline or venlafaxine extended-release, each with single-blind adjunctive placebo. Subjects with an inadequate response (Ͻ50% reduction HAM-D17 Total, HAM-D 17 Ն 14 and Clinical Global Impressions-Improvement [CGI-I] Ն 3 at the end of the ADT phase) continued ADT and were randomly assigned to adjunctive placebo or adjunctive aripiprazole; subjects were blinded to randomization (ie, the use of single-blind placebo). In the Marcus et al study, a total of 381 patients were randomized to adjunctive placebo (n = 190) or adjunctive aripiprazole (n = 191) in the randomized, double-blind treatment phase (Marcus et al 2008) . In the Berman et al study, a total of 178 patients were randomly assigned to adjunctive placebo and 184 to adjunctive aripiprazole (Berman et al 2007b) . It is also notable that, in both studies, the use of benzodiazepines or other sleep aids were not permitted, so that sedation/somnolence-inducing agents would not confound the effi cacy results. In both studies, remission rates (defi ned as a MADRS Total score of Յ10 and Ն50% reduction in MADRS Total score from baseline [end of prospective treatment]) were signifi cantly higher with adjunctive aripiprazole than with adjunctive placebo: 26.0% versus 15.7%, p = 0.01 (Berman et al 2007b) ; and 25.4% versus 15.2%, p Ͻ 0.05 (Marcus et al 2008) . Remission was achieved in signifi cantly more patients with adjunctive aripiprazole versus placebo early in both studies, as early as week 1 (Berman et al 2007b) and week 2 (Marcus et al 2008) .
Although remission is critical as an endpoint in real-life practice, for registration purposes the primary endpoint of these studies was the mean change in MADRS Total score from baseline to Week 6. Both studies showed signifi cant improvements with adjunctive aripiprazole over placebo on this measure: −8.8 vs −5.8, p Ͻ 0.001 (Berman et al 2007b) ; −8.5 vs −5.7, p = 0.001 (Marcus et al 2008) (Figure 4) . Again, the onset of a signifi cant difference with adjunctive aripiprazole over placebo was apparent by week 1 in the study by Marcus et al (2008) and week 2 in the study by Berman et al (2007b) , with the adjunctive aripiprazole group continuing to show improvement throughout the study. Response, defi ned as Ն50% improvement in MADRS total score from baseline, was achieved by signifi cantly more patients in the adjunctive aripiprazole than adjunctive placebo group in both studies at endpoint. Additional measures of effi cacy -the Clinical Global Impression of Severity (CGI-S) scores and Clinical Global Impression of Improvement (CGI-I) response rates -showed signifi cantly greater improvements with adjunctive aripiprazole compared with adjunctive placebo (p Ͻ 0.05).
Effi cacy in diffi cult-to-treat subgroups
In a post-hoc analysis, data from the two double-blind efficacy trials (effi cacy sample, n = 722) were pooled in order to determine the effi cacy of aripiprazole in subpopulations of patients with MDD. Although it has been suggested that antidepressants may be less effective in anxious depression (Fava et al 2008) and that tricyclics may be less effective in atypical depression, adjunctive aripiprazole showed signifi cantly greater effi cacy than placebo in patients with anxious depression (defi ned by a total score of Ն7 on the anxious/somatization factor of the HAM-D17) or atypical depression (defi ned using the Inventory for Depressive Symptomatology-Self Rated (IDS-SR) to determine the presence of DSM criteria for Major Depression with Atypical Features) (Thase et al 2007) . In addition, adjunctive aripiprazole was effective in both partial responders (Ն25% but Ͻ50% improvement on the MADRS Total score) and minimal responders (Ͻ25% improvement on the MADRS Total score). Change scores on the MADRS Total score were −7.2 with aripiprazole and −5.4 with placebo in partial responders and −9.4 with aripiprazole and −6.0 with placebo in minimal responders (Thase et al 2007) .
Tolerability
Overall in the clinical studies, adjunctive aripiprazole was well tolerated. There was a high completion rate in both studies (adjunctive aripiprazole, 87.9%; adjunctive placebo, 90.9% [Berman et al 2007b] ; adjunctive aripiprazole, 84.8%; adjunctive placebo, 85.3% [Marcus et al 2008] ), and a low discontinuation rate due to adverse events (AEs) (adjunctive aripiprazole, 3.3%; adjunctive placebo, 2.3% [Berman et al 2007b] ; adjunctive aripiprazole, 3.7%; adjunctive placebo, 1.1% [Marcus et al 2008] ). Akathisia was the most common AE reported with adjunctive aripiprazole in the two samples occurring in 24.8% of the patients. However, a post-hoc pooled analysis of the 737 patients in the two studies showed that akathisia was of mild to moderate severity in 92% of the cases, only 3 of 371 aripiprazole-treated patients (0.8%) discontinued treatment because of it, and half of the akathisia events resolved at endpoint. The most common interventions associated with resolution were dose reduction (51%) and no intervention (36%) (Nelson et al 2007) . 
Augmentation treatment in MDD
Because both of these studies used a "guided-flexible" dosing strategy that limited changes in aripiprazole dose to 5 mg in weekly increments and recommended a minimum dose of 10 mg/day, the rates of akathisia may overestimate rates obtained in clinical practice in which dosing is further individualized. Aiming for the minimum effective dose may be a prudent strategy. Indeed, in the Berman et al study, approximately half of the patients who completed the study and responded to adjunctive aripiprazole were receiving a dose of 10 mg/day or less (Berman et al 2007b) .
Mean weight gain with adjunctive aripiprazole was higher than adjunctive placebo in both studies (+2.01 ± 0.17 kg vs +0.34 ± 0.18 kg, p Ͻ 0.001 [Berman et al 2007b] ; +1.47 ± 0.16 kg vs +0.42 ± 0.17 kg, p Ͻ 0.001 [Marcus et al 2008] ) over a 6-week treatment period. Importantly, no patients in either study discontinued treatment due to weight gain. Signifi cantly, a pooled analysis of the metabolic parameters across both studies showed that the effects of adjunctive aripiprazole on mean change in body weight did not appear to be specifi c to any baseline body mass index category or to any dose of aripiprazole (Berman et al 2007a) . Furthermore, the increase in body weight occurred in the absence of a clinically signifi cant increase in other metabolic measures (Berman et al 2007a) . During the double-blind, randomized treatment phase in Berman et al, two patients experienced suicidal ideation, both in subjects who were receiving placebo (Berman et al 2007a) . In the second study, no suicide-related AEs were reported with either adjunctive aripiprazole or placebo during the double-blind randomized phase.
No new cases of tardive dyskinesia were observed during the study; however, the 6-week duration of the trials may underestimate rates observed with long-term treatment. Correll et al reviewed rates of tardive dyskinesia observed with the second-generation antipsychotics, and concluded that these rates (0.8% in non-elderly adults) were substantially lower than those observed with conventional agents (5.4% in adults on haloperidol) (Correll et al 2004) . Nevertheless, tardive dyskinesia can occur with all antipsychotic agents. The rate of tardive dyskinesia in populations with MDD treated with aripiprazole in the 1-year safety study (0.4%) (Berman et al 2008) was comparable to what has been reported for other atypicals in other populations in long-term studies (0.8%; Correll 2004) and lower than that seen with olanzapine-fl uoxetine combination (1.8%) (Corya et al 2003) . All of the cases resolved within 45 days of discontinuing medication.
Functioning
In addition to effi cacy for symptoms of major depression, an ideal treatment will also reduce or minimize functional disability associated with the disorder. The Sheehan Disability Scale (SDS) is an instrument used to assess the impact of illness-related impairment in three domains of functioning -work/school, social life, and family life/home responsibilities. Patients with MDD display greater functional impairment in social and family areas rather than work . Both the double-blind studies used the SDS and found that adjunctive treatment of standard ADT with aripiprazole improved family and social functioning (both p Ͻ 0.05). In addition, adjunctive aripiprazole treatment did not adversely affect sexual functioning in either study, as measured on the Sexual Function Index (SFI) scale, and resulted in signifi cant improvements in 'interest in sex' (p Ͻ 0.001) and 'sexual satisfaction' (p = 0.015) items during one of the studies (Marcus et al 2008) .
Conclusions
Achieving remission early in the course of depression is critical for the success of long-term treatment outcomes. A range of augmentation and combination strategies have been used in order to increase the chance of achieving remission. Indeed, for some patients, initiating combination and augmentation strategies earlier in treatment may increase the likelihood of remission; however, this strategy has not been well studied.
Although augmentation and combination strategies are commonly used for treatment of MDD, until recently there were relatively few large, double-blind, randomized, placebo-controlled trials to support this approach. As reviewed above, even the controlled trials used sample sizes that were usually very small. In addition, until recently treatment resistance was often poorly defi ned, if at all. The studies of the atypical antipsychotics are the fi rst class of augmentation strategies to attempt to defi ne unresponsive depression using adequate historical and prospective antidepressant trials. There is now growing evidence for the effi cacy of atypical antipsychotics for adjunctive treatment of depressive symptoms of MDD in the absence of psychotic symptoms. In two large clinical trials, the addition of aripiprazole to standard ADT monotherapy was signifi cantly more effective than the addition of placebo for the treatment of depression in patients with MDD who failed to respond to one prospective ADT trial and one to three historical trials during the current episode. Whether aripiprazole is more effective than other atypical agents has not been studied. Nor has the effi cacy of aripiprazole been compared with lithium, thyroid or other augmentation strategies. These questions, as well as the long-term use of these agents in depression, await further study.
Key clinical questions
How do you decide when to augment versus switch in MDD?
• Clinical wisdom, as refl ected in surveys and treatment choice in STAR*D, suggests that augmentation is favored in partial responders. This is primarily based on practical considerations -namely, that addition of a second agent allows the initial response to be maintained while a switch might not.
• However, in patients with minimal response, data comparing augmentation strategies with switch options are lacking.
• The tolerability of the initial agent plays a role here.
A poorly tolerated initial agent suggests a switch. Is there an accepted defi nition of inadequate treatment response/partial response or treatment-resistant patients?
• No defi nition of treatment-resistant depression has been adequately validated.
• Lack of response to a minimum of two adequate trials of medication from different classes has been proposed as the basic defi nition of treatment resistance in MDD (Thase 2002 ).
• The STAR*D findings suggest that remission rates drop considerably after two failed trials, supporting the recommendation that two failed trials defi nes treatment resistance. How does onset of action infl uence your decision when choosing a pharmacologic agent for MDD?
• Antidepressant medications are generally considered to have a delayed onset of action.
• In STAR*D, one half of the patients achieved remission during weeks 6-12.
• However, evidence of initial response can be observed in 1 or 2 weeks.
• Compared with switching, augmentation strategies may be more rapid, especially since no time is lost tapering the initial treatment.
• Early response to antidepressants is an unmet medical need and one that should be addressed in future treatment paradigms. How can we manage side effects of adjunctive aripiprazole therapy?
• The key to successful treatment with any agent is awareness of the clinical profi le and education of the patient about the drugs used.
• As clinical experience with aripiprazole has grown, some management strategies for the treatment of side effects have emerged.
• Although few predictors of akathisia have been identifi ed, in patients with a history of akathisia, a more gradual dosing strategy might be used. Rates of akathisia appear higher in patients under age 40 years.
• For mild-moderate akathisia, dose reduction is an option if it does not compromise effi cacy. If tolerable, akathisia appears to abate with time.
• Concomitant medications (eg, benzodiazepines, betablockers, or anticholinergic agents) may be useful for more severe akathisia but their effi cacy in this situation is based more on clinical experience than controlled trials. Given high rates of improvement with time, it is not clear that these interventions are better than time.
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